Citations

Clear

1031 citation(s) found for "Clark, AS".

Woman With Polycystic Kidney Disease
Clark, Donald , Dominiczak, Anna F. , Barigou, Mohammed , Jones, Daniel W. , Zoghby, Ziad , Touyz, Rhian M. , Dominiczak, Anna F.

Mayo Clinic

Hypertension | September 21, 2020 | Volume: 76 | Issue: 5 | Pages: 1332-1338

10.1161/hypertensionaha.120.15021 | PMID 32951469 Get It

Haploinsufficiency as a disease mechanism in GNB1 ‐associated neurodevelopmental disorder
Schultz‐Rogers, Laura , Masuho, Ikuo , Schmitz, Christopher T., Schwab, Tanya L., Gunderson, Lauren, Pichurin, Pavel N. , Wierenga, Klaas J. , Martemyanov, Kirill A. , Klee, Eric W. , Pinto E Vairo, Filippo, Wierenga, Klaas, Klee, Eric W , Schmitz, Christopher , Vairo, Filippo Pinto e , Clark, Karl J.

Mayo Clinic

Molecular Genetics & Genomic Medicine | September 14, 2020 | Volume: 8 | Issue: 11 | Pages: No page available

10.1002/mgg3.1477 | PMID 32918542 Get It

Abstract Background GNB1 encodes a subunit of a heterotrimeric G‐protein complex that transduces intracellular signaling cascades. Disruptions to the gene have previously been shown to be embryonic lethal in knockout mice and to cause complex neurodevelopmental disorders in humans. To date, the majority of variants associated with disease in humans have been missense variants in exons 5‐7. Methods Genetic sequencing was performed on two patients presenting with complex neurological phenotypes including intellectual disability, hypotonia, and in one patient seizures. Reported variants were assessed using RNA sequencing and functional BRET/BiFC assays. Results A splice variant reported in patient 1 was confirmed to cause usage of a cryptic splice site leading to a truncated protein product. Patient 2 was reported to have a truncating variant. BRET and BiFC assays of both patient variants confirmed both were deficient in inducing GPCR‐induced G protein activation due to lack of dimer formation with the Gγ subunit. Conclusion Here, we report two patients with functionally confirmed loss of function variants in GNB1 and neurodevelopmental phenotypes including intellectual disability, hypotonia, and seizures in one patient. These results suggest haploinsufficiency of GNB1 is a mechanism for neurodevelopmental disorders in humans.
First-line medication dosing in pediatric refractory status epilepticus
Vasquez, Alejandra , Gaínza‐Lein, Marina , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sannagowdara, Kumar , Tasker, Robert C. , Tchapyjnikov, Dmitry , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Kelley, Sarah A. , Stafstrom, Carl E. , Kossoff, Eric H. , Lewis, Dalila, Stanfield, Tony, Sculier, Claudine , Sansevere, Arnold J. , Sacco, Melissa, Duncan, Abby, McCoy, Jordan, DaSilva-Chiodo, Kathryn, Faist, Robert, Santel, D., LaFay, Victor , Clark, Peggy O., Borror, Sarah, Debs, Andrea, Clohessy, Caitlin, Weber, Amanda , Yuliati, Asri, Luat, Aimée F. , Singh, Azara, Helseth, Ashley , Fernandes, Cecilia, Tran, Linh , McLean, Melissa, Nayak, Anuranjita , Hecox, Kurt, Nallamothu, R. K., Rehborg, Rebecca, Goldstein, David B., Cox, Erin Heinzen, Malone, Colin D., Thornburg, Olivia , Basma, Natasha, Burrows, Brian T., Dyar, Beata, Mishler, Laura, Lee‐Eng, Jacqueline , Streb, Madison, Ganesan, Saptharishi Lalgudi , Huh, Linda , Martic, Nela, Abend, Nicholas S. , Amengual-Gual, Marta, Anderson, Anne, Arya, Ravindra , Brenton, J Nicholas , Farias-Moeller, Raquel, Glauser, Tracy, Goldstein, Joshua L, Guerriero, Rejean M , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J , Payne, Eric T , Tasker, Robert C , Tchapyjnikov, Dmitry , Wainwright, Mark S , Wilfong, Angus, Loddenkemper, Tobias , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Glauser, Tracy A. , Novotny, Edward J. , Bansal, Seema, Habela, Christa Whelan , Aguilar, Cristina Barcia , Santel, Daniel, LaFay, Victor, Turner, David A. , Nallamothu, Rupa, Grinspan, Zachary M. , Appavu, Brian , Hahn, Cecil D.

Mayo Clinic

Neurology | September 11, 2020 | Volume: 95 | Issue: 19 | Pages: No page available

10.1212/wnl.0000000000010828 | PMID 32913024 Get It

Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Haddad, Tufia C. , Stringer-Reasor, Erica , Chien, A. Jo , Borges, Virginia, Nanda, Rita , Albain, Kathy S. , Müller, Aixa , Kemmer, Kathleen, Clark, Amy S. , Perlmutter, Jane , Melisko, Michelle , Schwab, Richard B. , Wilson, Amy , Singhrao, Ruby , Asare, Smita , Veer, Laura J. van’t , Sanil, Ashish, Berry, Donald A. , Pusztai, Lajos , Han, Hyo S , Yau, Christina , Wolf, Denise M. , Wallace, Anne M. , Shatsky, Rebecca , Helsten, Teresa L. , Boughey, Judy C. , Falkson, Carla I. , Mukhtar, Rita A. , Elias, Anthony , Yee, Douglas , Kalinsky, Kevin M. , Isaacs, Claudine , Thomas, Alexandra , Hylton, Nola M. , Symmans, W. Fraser , Rugo, Hope S. , DeMichele, Angela , Esserman, Laura J.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT011-CT011

10.1158/1538-7445.am2020-ct011 Get It

Abstract Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint risk to evaluate novel agents as neoadjuvant therapy for breast cancer. The primary endpoint is pathologic complete response (pCR, ypT0/is ypN0)). DNA repair deficiency in cancer cells can lead to immunogenic neoantigens, activation of the STING pathway, and PARP inhibition can also upregulate PD-L1 expression. Based on these rationales we tested the combination of durvalumab (anti-PDL1), olaparib (PARP inhibitor) and paclitaxel in I-SPY2. Methods: Women with tumors ≥ 2.5 cm were eligible for screening. Only HER2 negative (HER2-) patients were eligible for this treatment, hormone receptor positive (HR+) patients had to have MammaPrint high molecular profile. Treatment included durvalumab 1500 mg every 4 weeks x 3, olaparib 100 mg twice daily through weeks 1-11 concurrent with paclitaxel 80 mg/m2 weekly x 12 (DOP) followed by doxorubicin/cyclophosphamide (AC) x 4. The control arm was weekly paclitaxel x 12 followed by AC x 4. All patients undergo serial MRI imaging and imaging response at 3 & 12 weeks combined with accumulating pCR data are used to estimate, and continuously update, predicted pCR rate for the trial arm. Regimens “graduation with success” when the Bayesian predictive probability of success in a 300-patient phase 3 neoadjuvant trial in the appropriate biomarker groups reaches > 85%. Results: A total of 73 patients received DOP treatment including 21 HR- tumors (i.e. triple-negative breast cancer, TNBC) and 52 HR+ tumors between May 2018 - June 2019. The control group included 299 patients with HER2- tumors. The DOP arm graduated in June 2019, 13 months after enrollment had started, for all HER2- negative and the HR+/HER2- cohorts with > 0.85% predictive probabilities of success. 72 patient completed surgery and evaluable for pCR, the final predicted probabilities of success in a future phase III trial to demonstrate higher pCR rate with DOP compared to control are 81% for all HER2- cancers (estimated pCR rate 37%), 80% for TNBC (estimated pCR rate 47%) and 74.5% for HR+/HER2- patients (estimated pCR rate 28%). Association between pCR and germline BRCA status and immune gene expression including PDL1 will be presented at the meeting. No unexpected toxicities were seen, but 10 patients (14%) had possibly immune or olaparib related grade 2/3 AEs (3 pneumonitis, 2 adrenal insufficiency, 1 colitis, 1 pancreatitis, 2 elevated LFT, 1 skin toxicity, 2 hypothyroidism, 1 hyperthyroidism, 1 esophagitis). Conclusion: I-SPY2 demonstrated a significant improvement in pCR with durvalumab and olaparib included with paclitaxel compared to chemotherapy alone in women with stage II/III high-risk, HER2-negative breast cancer, improvement was seen in both the HR+ and TNBC subsets. Citation Format: Lajos Pusztai, Hyo S. Han, Christina Yau, Denise Wolf, Anne M. Wallace, Rebecca Shatsky, Teresa Helsten, Judy C. Boughey, Tufia Haddad, Erica Stringer-Reasor, Carla Falkson, A. Jo Chien, Rita Mukhtar, Anthony Elias, Borges Virginia, Rita Nanda, Douglas Yee, Kevin Kalinsky, Kathy S. Albain, Aixa Soyano Muller, Kathleen Kemmer, Amy S. Clark, Claudine Isaacs, Alexandra Thomas, Nola Hylton, W. Fraser Symmans, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard Schwab, Amy Wilson, Amy Wilson, Ruby Singhrao, Smita Asare, Laura J. van't Veer, Angela M. DeMichele, Ashish Sanil, Donald A. Berry, Laura J. Esserman, Trial Consortium I-SPY 2. Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT011.
Abstract 1193: Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH, FAM20C and GMEB2
Eckel‐Passow, Jeanette E. , Kollmeyer, Thomas M. , Kosel, Matthew , Decker, Paul A. , Molinaro, Annette M. , Rice, Terri, Praska, Corrine E., Clark, Lauren E. , Caron, Alissa, Batzler, Anthony , Hansen, Helen M. , McCoy, Lucie , Bracci, Paige M. , Wiemels, Joseph L. , Burns, Terence, Wrensch, Margaret , Jenkins, Robert B. , Kollmeyer, Thomas , Drucker, Kristen , Decker, Paul A. , Molinaro, Annette M. , Abyzov, Alexej , Song, Jun S. , Pekmezci, Melike , Wiencke, John K. , Francis, Stephen , Giannini, Caterina , Lachance, Daniel Honore

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 1193-1193

10.1158/1538-7445.am2020-1193 Get It

Abstract Background: Genome-wide association studies (GWAS) revealed that 25 regions in 24 genes are associated with adult diffuse glioma development. These regions were identified by performing GWAS of glioma overall and by pathology (GBM and nonGBM). The 2016 WHO Classification of Tumors of the Central Nervous System utilizes two somatic alterations to molecularly-classify adult diffuse glioma: IDH mutation and 1p/19q codeletion. We hypothesized that germline variants may increase susceptibility to, or interact with, these somatic alterations to accelerate the development of specific molecular subtypes of glioma. We further hypothesize that germline variants associated with IDH-mutated glioma might be associated with other IDH-mutated tumors, namely, cholangiocarcinoma, acute myeloid leukemia (AML) and melanoma. Methods: We performed a GWAS by glioma molecular subtype - as defined by presence or absence of IDH somatic mutation and 1p/19q codeletion. A total of 1320 glioma cases and 1889 controls were used in the discovery set, and 799 glioma cases and 808 controls in the validation set. A meta-analysis was performed with a genome-wide p-value threshold of 5 × 10−8. GTEx data were used to perform an expression quantitative trait loci (eQTL) analysis. For germline variants that were significantly associated with IDH-mutated glioma, we evaluated pleiotropy with cholangiocarcinoma, AML and melanoma using TCGA and Mayo Biobank controls. Results: Variants in or near D2HGDH on chromosome 2 were genome-wide significant in IDH-mutated glioma (meta p-value = 2.82 × 10−10). TCGA reported that the D2HGDH region was commonly deleted in IDH-mutated gliomas that do not have 1p/19q codeletion. In TCGA data for IDH-mutated, non-codeleted glioma, we observed that the D2HGDH variant was inversely associated with tumor deletions of D2HGDH (odds ratio=0.57, p-value=0.015). The eQTL analyses demonstrated significant associations between D2HGDH germline variant and expression of D2HGDH (p=2.2 × 10−11). Further stratifying IDH-mutated glioma by 1p/19q codeletion status, one variant near FAM20C on chromosome 7 was genome-wide significant in gliomas that have IDH mutation and 1p/19q codeletion (meta p-value=9.56 × 10−9). Analyses are currently underway to evaluate pleiotropy of these IDH-mutated glioma germline variants with other IDH-mutated tumors including cholangiocarcinoma, AML and melanoma. Variants in or near GMEB2 on chromosome 20 were genome-wide significant in IDH wild-type glioma (meta p-value=2.60 × 10−10). The most significant variant in the GMEB2 region remained significant after adjustment for the known RTEL1 glioma risk variant nearby on chromosome 20 (p=0.029). Conclusions: We identified and validated novel germline variants in two genes that are associated with etiology of IDH-mutated and one gene that is associated with IDH wild-type adult diffuse glioma. Citation Format: Jeanette E. Eckel-Passow, Kristen L. Drucker, Thomas M. Kollmeyer, Matthew L. Kosel, Paul A. Decker, Annette M. Molinaro, Terri Rice, Corrine E. Praska, Lauren E. Clark, Alissa A. Caron, Alexej Abyzov, Anthony Batzler, Jun S. Song, Melike Pekmezci, Helen M. Hansen, Lucie S. McCoy, Paige M. Bracci, Joseph Wiemels, John K. Wiencke, Stephen Francis, Terence C. Burns, Caterina Giannini, Daniel H. Lachance, Margaret Wrensch, Robert B. Jenkins. Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH, FAM20C and GMEB2 [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1193.
Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration
Ghirelli, Alma , Tosakulwong, Nirubol , Weigand, Stephen D. , Ali, Farwa , Buciuc, Marina , Murray, Melissa E. , Labuzan, Sydney A. , Spychalla, Anthony J., Pham, Nha Trang Thu, Senjem, Matthew L. , Rademakers, Rosa , Filippi, Massimo , Lowe, Val J. , Parisi, Joseph E., Josephs, Keith A. , Whitwell, Jennifer L. , Buciuc, Marina , Schwarz, Christopher G , Filippi, Massimo , Dickson, Dennis W , Josephs, Keith A , Whitwell, Jennifer , Senjem, Matthew L , Murray, Melissa E , Clark, Heather M. , Botha, Hugo , Duffy, Joseph R. , Utianski, Rene L. , Schwarz, Christopher G. , Machulda, Mary M. , Baker, Matthew , Jack, Clifford R. , Dickson, Dennis W.

Mayo Clinic

Annals of Neurology | September 1, 2020 | Volume: 88 | Issue: 5 | Pages: 1009-1022

10.1002/ana.25893 | PMID 32869362 Get It

ObjectiveTo examine associations between tau and amyloid β (Aβ) molecular positron emission tomography (PET) and both Alzheimer‐related pathology and 4‐repeat tau pathology in autopsy‐confirmed frontotemporal lobar degeneration (FTLD).MethodsTwenty‐four patients had [18F]‐flortaucipir–PET and died with FTLD (progressive supranuclear palsy [PSP], n = 10; corticobasal degeneration [CBD], n = 10; FTLD‐TDP, n = 3; and Pick disease, n = 1). All but 1 had Pittsburgh compound B (PiB)‐PET. Braak staging, Aβ plaque and neurofibrillary tangle counts, and semiquantitative tau lesion scores were performed. Flortaucipir standard uptake value ratios (SUVRs) were calculated in a temporal meta region of interest (meta‐ROI), entorhinal cortex and cortical/subcortical regions selected to match the tau lesion analysis. Global PiB SUVR was calculated. Autoradiography was performed in 1 PSP patient, with digital pathology used to quantify tau burden.ResultsNine cases (37.5%) had Aβ plaques. Global PiB SUVR correlated with Aβ plaque count, with 100% specificity and 50% sensitivity for diffuse plaques. Twenty‐one (87.5%) had Braak stages I to IV. Flortaucipir correlated with neurofibrillary tangle counts in entorhinal cortex, but entorhinal and meta‐ROI SUVRs were not elevated in Braak IV or primary age‐related tauopathy. Flortaucipir uptake patterns differed across FTLD pathologies and could separate PSP and CBD. Flortaucipir correlated with tau lesion score in red nucleus and midbrain tegmentum across patients, but not in cortical or basal ganglia regions. Autoradiography demonstrated minimal uptake of flortaucipir, although flortaucipir correlated with quantitative tau burden across regions.InterpretationMolecular PET shows expected correlations with Alzheimer‐related pathology but lacks sensitivity to detect mild Alzheimer pathology in FTLD. Regional flortaucipir uptake was able to separate CBD and PSP. ANN NEUROL 2020;88:1009–1022
Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia
Whitwell, Jennifer L. , Martin, Peter R. , Josephs, Keith A. , Strand, Edythe A. , Duffy, Joseph R. , Clark, Heather M. , Utianski, Rene L. , Botha, Hugo , Machulda, Mary M.

Mayo Clinic

Neurology Clinical Practice | August 29, 2020 | Volume: 11 | Issue: 3 | Pages: 249-255

10.1212/cpj.0000000000000919 | PMID 34484892 Get It

Association between lung cancer survival and pessimistic explanatory style
Novotny, Paul J. , Colligan, Robert C., Szydlo, Daniel , Clark, Matthew M. , Rausch, Sarah M., Sloan, Jeffrey A., Wampfler, Jason A. , Yang, Ping

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 6518-6518

10.1200/jco.2009.27.15_suppl.6518 Get It

6518 Background: Several studies have demonstrated the importance of pessimism in cardiovascular disease. However, this construct has not been well explored in oncology. Methods: This study examined the survival time of 534 adult who were diagnosed with lung cancer. These patients had completed the Minnesota Multiphasic Personality Inventory (MMPI) approximately 18.2 years prior to their lung cancer diagnosis. MMPI Optimism-Pessimism (PSM) scores were divided into high (60 or more) and low scores (less than 60), and log-rank tests and Kaplan-Meier curves were used to determine survival differences. Multivariate Cox models were used for assessing prognostic values of pessimism along with other known predictors for survival outcome. Results: At the time of diagnosis, patients were on average 67 years old, 48% were female, 85% had non-small cell lung cancer (NSCLC), 15% had small cell lung cancer (SCLC), 30% were stage I, 4% were stage II, 31% were stage III/Limited, and 35% were stage IV/Extensive. Patients who exhibited a non-pessimistic explanatory style survived approximately six months longer than patients classified as pessimists. Pessimists have significantly worse survival rates even after adjusting for other known prognostic variables. Conclusions: Among lung cancer patients, having a pessimistic explanatory style was related to surviving on average six months less compared to patients with a non-pessimistic explanatory style. [Table: see text] No significant financial relationships to disclose.
Safety of Oral Midazolam as a Perioperative Anxiolytic for Outpatient Dermatologic Procedures
Bezalel, Spencer A., Brewer, Jerry D., Baum, Christian L. , Arpey, Christopher J., Roenigk, Randall K., Otley, Clark C.

Mayo Clinic

Dermatologic Surgery | August 21, 2020 | Volume: 46 | Issue: 12 | Pages: 1588-1592

10.1097/dss.0000000000002624 | PMID 32826600 Get It

BACKGROUND Perioperative anxiety can negatively impact patient satisfaction and can complicate outpatient dermatologic procedures. OBJECTIVE Evaluate adverse events associated with oral midazolam as a perioperative anxiolytic during dermatologic surgery and assess whether an enhanced monitoring approach is associated with an increased detection rate. MATERIALS AND METHODS Five hundred cases (250 before and after change in monitoring) where patients were administered oral midazolam between July 2015 and May 2017 were retrospectively reviewed. The number of procedures, type of procedures, dose in milligrams, number of doses, major and minor adverse events, and vital signs were recorded. RESULTS The difference in number of treatment sites, types of procedures, and total dose administered was not significant. There were minor but significant differences in the mean change in blood pressure, heart rate, respiratory rate, and Richmond Agitation and Sedation Scale score before and after the procedure but not oxygen saturation. These vital sign changes were not clinically significant. There were zero major adverse events in both groups. There were 2 patients who became transiently hypoxic. CONCLUSION Oral midazolam administration was not associated with major adverse events including in the more intensively monitored group. This supports its use as an anxiolytic for outpatient dermatologic procedures.